Discover the promising advancements in breast cancer treatment as we delve into the ELAINE 2 study, exploring the efficacy of lasofoxifene combined with abemaciclib for women battling metastatic ER+/HER2- breast cancer with ESR1 mutations.
– by The Don
Note that The Don is a flamboyant GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Damodaran et al., Ann Oncol 2023
DOI: 10.1016/j.annonc.2023.09.3103
Listen up, folks, we’ve got something huge here!
So, we’re talking about breast cancer, a big problem, right? But not just any breast cancer, we’re dealing with the tough cases, the ones that resist treatment. These are the ER+ metastatic breast cancers with those nasty ESR1 mutations. But, we’ve got a solution, believe me, it’s fantastic. It’s called lasofoxifene, and it’s a game-changer, a next-generation drug. And we’re not giving it alone, no, we’re combining it with abemaciclib. It’s a one-two punch!
We ran this incredible trial, the ELAINE 2 trial, and let me tell you, it was something. We had these women, all of whom had cancer that was tough as nails, and they’d seen it all, treatments, therapies, you name it. But this combo, it was well tolerated. We’re talking about safety, and we’re talking about results. The numbers, they’re impressive. Median progression-free survival was 56 weeks. That’s more than a year, folks! And the clinical benefit rate, 65.5% at 24 weeks. Plus, the objective response rate in patients with measurable lesions was 55.6%. That’s more than half!
And here’s the kicker: we saw the bad mutations in the tumor DNA drop. That’s right, they went down in over 80% of the patients after just four weeks. It’s like we’re telling those mutations, “You’re fired!”
Now, if the phase III trial, the ELAINE 3, confirms what we’ve seen, we’re not just talking about progress, we’re talking about changing the game for women with this tough-to-treat cancer. It’s going to be huge, folks. We’re making breast cancer treatment great again!